Developed in the wake of the COVID-19 pandemic, ReVAMPP will support a coordinating center and seven research centers, including VUMC, with a focus on nine virus groups that pose the greatest risk to human health.

Researchers must continually chase funding for their work. Kelly Dooley's prestigious award from the NIH is intended to help provide respite from that chase.

A multicenter study conducted in 19 states between October 2023 and March 2024 demonstrated that RSV vaccination was 75% effective in preventing RSV-associated hospitalizations for adults age 60 and older.

Staph is a leading bacterial cause of death from bloodstream, bone and joint infections, in part because of high rates of antibiotic treatment failure.

VUMC’s antibody collaboration with the DOD goes back to 2018, when the medical center signed a five-year cooperative agreement with the U.S. Defense Advanced Research Projects Agency to develop protective treatments that can be rushed to health care providers within weeks after a viral outbreak.

Sweeping data integration and clinical trial simulations are needed to help decide which targets to prioritize in researching new tuberculosis treatment regimens.

The Strategies and Treatments for Respiratory Infections and Viral Emergencies network includes more than 300 sites around the world and international experts in clinical trials, infectious diseases, critical care and pandemic preparedness.